Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An update from Marinus ( (MRNS) ) is now available.
On February 11, 2025, Immedica Pharma AB completed its acquisition of Marinus Pharmaceuticals, Inc., following a successful tender offer to purchase all outstanding shares for $0.55 per share. This transaction resulted in Marinus becoming an indirect wholly-owned subsidiary of Immedica, leading to the delisting of Marinus’ common stock from NASDAQ. The acquisition led to significant changes in Marinus’ management, with new appointments and the termination of former directors and officers. The total consideration for the merger was approximately $32.3 million, excluding related transaction fees and expenses.
More about Marinus
Marinus Pharmaceuticals is a commercial-stage pharmaceutical company focused on developing innovative therapeutics for seizure disorders. Its primary product, ZTALMY® (ganaxolone) oral suspension CV, is an FDA-approved medication for seizure management, introduced in the United States in 2022.
YTD Price Performance: 3.00%
Average Trading Volume: 1,813,180
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $30.34M
For a thorough assessment of MRNS stock, go to TipRanks’ Stock Analysis page.
